The present study aimed at the evaluation of [68Ga]Pentixafor PET/CT as a novel and powerful tool for sensitive, non-invasive in vivo quantification of CXCR4 in preclinical models of MM and in a clinical pilot assessment investigating patients with advanced MM. This evidence concerns the gene CXCR4 and Miyoshi myopathy.